ORIGINAL RESEARCH article
Front. Oncol.
Sec. Cancer Epidemiology and Prevention
Volume 15 - 2025 | doi: 10.3389/fonc.2025.1599759
This article is part of the Research TopicStrategies to Improve Awareness and Management of Cancer Risk Factors and ScreeningsView all 8 articles
BI-RADS Application for Breast Cancer Screening in Primary Healthcare Settings: Assessing Protocol Adherence and Diagnostic Validity
Provisionally accepted- 1Department of Radiology, Affiliated Cancer Hospital of Zhengzhou University & Henan Cancer Hospital, Zhengzhou, China
- 2Department of Cancer Epidemiology,Affiliated Cancer Hospital of Zhengzhou University & Henan Cancer Hospital, Zhengzhou, China
Select one of your emails
You have multiple emails registered with Frontiers:
Notify me on publication
Please enter your email address:
If you already have an account, please login
You don't have a Frontiers account ? You can register here
Abstract Background The application performance of the Breast Imaging-Reporting and Data System (BI-RADS) in primary healthcare settings remains uncertain. The normativity of BI-RADS classification and the efficacy of breast cancer detection guided by BI-RADS classification were evaluated here. Methods All data used in the current study were derived from a breast cancer screening cohort baseline database, which consists of 8,996 women aged 35-64 years from Central China. Participants aged 35-44 underwent automated breast ultrasound (ABUS) and handheld ultrasound (HHUS), while those aged 45-64 were screened with ABUS, HHUS, and mammography (MG). All imaging diagnoses were made by radiologists according to the BI-RADS 5th edition classification system published by the ACR in 2013. The distribution of malignant imaging findings and inter-modality agreement on BI-RADS classifications were assessed. Based on pathological results, the area under the receiver operating characteristic (ROC) curve (AUC) was used to assess the performance of breast cancer screening according to BI-RADS-guided referrals. Results Of individuals found with irregular morphology, 44%, 45.7% and 77.4% were detecting 删除[dell]: old 删除[dell]: Handheld 删除[dell]: 上标 设置格式[123]: was 删除[dell]: ly 删除[dell]: there were 删除[123]: classified as BI-RADS category 4 or higher for HHUS, ABUS and MG, respectively; For those with indistinct margins, the proportion was 81%, 77.5% and 40.8%, correspondingly; For grouped calcifications, they were 100% for HHUS and 85.7% for MG; Meanwhile, 72.7% and 88.9% not parallel (taller than wide) masses were categorized as BI-RADS category 4 for HHUS and ABUS. The concordance of BI-RADS classification was as high as 98.2% between HHUS and ABUS (Kappa = 0.726), whereas it was about 96% between ultrasound and MG (Kappa ranged from 0.21 to 0.25). The BI-RADS guided screening performance for breast cancer showed AUC values of 0.9935 for ABUS, 0.9529 for HHUS, 0.8983 for MG. If the BI-RADS diagnosis of MG was considered in ultrasound-negative women, only the HHUS's performance was boosted, achieving an AUC of 0.9920. Conclusions Radiologists at primary hospitals can effectively apply BI-RADS based on the malignant features they found. BI-RADS can provide a reliable framework for guiding breast cancer screening in primary healthcare settings.
Keywords: BI-RADS, breast cancer screening, Primary healthcare setting, automated breast ultrasound, handheld ultrasound, Mammography
Received: 25 Mar 2025; Accepted: 26 Sep 2025.
Copyright: © 2025 Li, Xu, Wang, Zhang, Zheng and Li. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) or licensor are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
* Correspondence: Hai-Liang Li, lihailianggy@163.com
Disclaimer: All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.